Delivery Order SPE2DB20D1100-SPE2DB25FD9F3
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 21, 2025, for the supply of Xolair 75 mg/0.5 ml syringes with a ceiling value of $1,080.54 and a firm fixed price structure. This delivery order is non-set-aside and represents a competitively awarded contract with an ultimate completion date of August 11, 2025. The product will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 29, 2025, for the supply of XOLAIR 150 mg/ml syringes, with a contract ceiling value of $5,762.72 and an ultimate completion date of August 19, 2025. This firm fixed-price delivery order represents a competitively awarded contract with no set-aside designation, performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The contract falls under AmerisourceBergen's broader...
- The Defense Logistics Agency awarded a delivery order valued at $4,905.08 to AmerisourceBergen Drug Corp for the supply of Xolair 300 mg/2 ml syringes on July 31, 2025, with an ultimate completion date of August 21, 2025. This non-set-aside, competitively awarded contract utilizes firm fixed pricing and represents a child delivery order under AmerisourceBergen's larger indefinite delivery contract with DLA Troop Support Medical. The product will be delivered to the company's corporate office...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 29, 2025, for the supply of Xolair 150 mg/ml syringes, with a contract ceiling value of $5,402.58 and an ultimate completion date of August 19, 2025. This is a firm fixed price delivery order with no set-aside designation, competitively awarded under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a $999.99 billion pharmaceutical supply vehicle...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Xolair 150 mg/mL syringes, valued at $2,161.02, with an ultimate completion date of August 22, 2025. This contract was awarded on August 1, 2025, under a firm fixed-price delivery order with no set-aside designation, indicating competitive award. The place of performance is AmerisourceBergen's location in Conshohocken, Pennsylvania. This delivery order is issued under the company's larger...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 22, 2025, for the supply of Xolair 300 mg/2 mL auto-injector units. This competitively awarded, non-set-aside contract has a ceiling value of $63,766.40 with a firm fixed price structure and an ultimate completion date of August 12, 2025. The place of performance is the contractor's facility in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 31, 2025, for the supply of Xolair 300 mg/2 mL auto-injectors with a ceiling value of $3,188.32. This firm fixed-price, competitively awarded delivery order is scheduled for completion by August 21, 2025, and will be performed at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. The award represents a single delivery order issued under AmerisourceBergen's larger indefinite delivery...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 5, 2025, for the supply of Xolair 300 mg/2 ml auto-injector doses with a ceiling value of $1,594.16 and a firm fixed price arrangement. The contract, which represents a non-set-aside, competitively awarded procurement, is scheduled for ultimate completion by August 26, 2025. This delivery order is issued under AmerisourceBergen's broader Indefinite Delivery Contract with DLA Troop Support Medical...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 21, 2025, for the supply of Xolair 300 mg/2 ml syringes, with a ceiling value of $20,786.28 and a firm fixed price contract type. The delivery order, which represents a child contract under a larger indefinite delivery vehicle, is scheduled for completion by August 11, 2025, with performance taking place at the contractor's facility in Conshohocken, Pennsylvania. This award was made through open...
- The Defense Logistics Agency awarded a $3,241.54 delivery order to AmerisourceBergen Drug Corp for Xolair 150 mg/ml syringes, with an ultimate completion date of August 21, 2025. This competitively awarded, firm fixed-price contract carries no set-aside designation and represents a direct procurement of pharmaceutical supplies for federal medical needs. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, will perform this delivery order from its corporate office location. This...
- SPE2DB20D1100Indefinite Delivery Contract
- SPE2DB20D1100-SPE2DB25FD9F3Delivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Xolair 300 mg/2 mL syringes on August 7, 2025, with a ceiling value of $1,732.19 and an ultimate completion date of August 28, 2025. This firm fixed-price delivery order represents a competitive, non-set-aside award and is performed from the vendor's corporate office location in Conshohocken, Pennsylvania. The delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, a $999.9 billion prime contract valued through December 2026 that serves as a comprehensive global pharmaceutical support vehicle for military healthcare programs worldwide. AmerisourceBergen Drug Corp is a major pharmaceutical distributor and healthcare solutions provider that serves as a critical vendor for federal medical procurement, particularly supporting military and veteran healthcare systems through the Defense Logistics Agency's Medical Supply Chain. The company's substantial IDC portfolio demonstrates its capability to deliver a wide range of pharmaceutical products and medical supplies across multiple therapeutic domains to the Defense Health Agency, U.S. Coast Guard, and other government healthcare systems. This delivery order for Xolair, a specialty pharmaceutical product, exemplifies the company's ongoing role in fulfilling federal medical supply requirements through competitively awarded contracts with firm fixed pricing structures.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.7k | 8/7/25 |